Last reviewed · How we verify
Ginseol Kg1 (low dose)
Ginseol KG1 is a ginseng-derived compound that modulates immune function and metabolic pathways to improve clinical outcomes in disease states.
Ginseol KG1 is a ginseng-derived compound that modulates immune function and metabolic pathways to improve clinical outcomes in disease states. Used for Immune function enhancement (Phase 3 investigational).
At a glance
| Generic name | Ginseol Kg1 (low dose) |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Herbal extract / Immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Immunology / General wellness |
| Phase | Phase 3 |
Mechanism of action
Ginseol KG1 is an active component extracted from Korean red ginseng that acts as an immunomodulator and antioxidant. It enhances natural killer cell activity and promotes balanced immune responses while reducing inflammatory markers. The compound may also improve metabolic parameters and tissue regeneration through multiple signaling pathways.
Approved indications
- Immune function enhancement (Phase 3 investigational)
Common side effects
- Gastrointestinal disturbance
- Insomnia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ginseol Kg1 (low dose) CI brief — competitive landscape report
- Ginseol Kg1 (low dose) updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI